2Q Revenues: $5.9 billion (+6%)
2Q Earnings: $1.2 billion (+31%)
YTD Revenues: $11.5 billion (+3%)
YTD Earnings: $2.8 billion (+42%)
Comments: Cymbalta sales increased 22% to $1.5 billion in the quarter. Cialis sales increased 13% to $529.4 million. Revenue in the U.S. increased 13% to $3.4 billion driven by increased prices, primarily for Cymbalta. Revenue outside the U.S. decreased 2% to $2.5 billion, impacted by foreign exchange rates, primarily the Japanese yen, and the loss of market exclusivity for Zyprexa (-25% to $283.2 million). Higher revenue and ongoing cost containment drove earnings growth.